Plant listing · Tahliwal, Una, Himachal Pradesh
GMP Pharmaceutical Unit for Sale in Una, Himachal Pradesh
A running, cGMP-approved oral solid and liquid plant at Phase III, Industrial Area Tahliwal, Tehsil Haroli, District Una — 12,000 sq. ft. constructed, licensed for tablets, capsules and syrups, asking price ₹6.5 crore.
At a glance
Facility overview
The unit was installed in 2022 and operates as a partnership entity, manufacturing generic and ethical products in tablet, capsule and syrup dosage forms. It runs its own purified water system and holds two separate manufacturing licences.
| Parameter | Details |
|---|---|
| Location | Phase III, Industrial Area Tahliwal, Tehsil Haroli, District Una, Himachal Pradesh |
| Year installed | 2022 |
| Land area | 800 square yards (approximately 7,200 sq. ft.) |
| Constructed area | 12,000 sq. ft. |
| Dosage forms licensed | Tablets, capsules, syrups |
| Certification | cGMP approved (state GMP) |
| Licences | Form 25 (No. NNZ/22/***) and Form 28 (No. MNZ/22/***), Drugs Control Authority, Dharamshala, Himachal Pradesh |
| Product range | 250+ formulations across 8 therapeutic categories |
| Third-party manufacturing | 30 client parties |
| Purified water system | 1,000 litres/hour generation, 2,000 litre overhead storage |
| Business model | Partnership entity · generic and ethical segment |
| EBITDA margin (seller-stated) | 15–25% |
| Asking price | ₹6.5 crore |
Location
Why Tahliwal, Una works as a manufacturing base
Tahliwal sits in Tehsil Haroli on the bank of the Swan river, about 16 km from Una town, and is one of the established industrial areas of the Una belt alongside Mehatpur, Gagret and Amb. Formulation and API units already operate here, so a buyer inherits access to ancillary suppliers, contract testing laboratories and a workforce that has worked in pharma before.
Connectivity
Road, rail and air links
- Chandigarh: roughly 110–130 km by road depending on route (via Nangal–Anandpur Sahib or via Nawanshahr).
- Nearest airport: Chandigarh International Airport, approximately 110 km. Gaggal (Kangra) is at a similar distance.
- Nearest railway: Una Himachal, approximately 16 km. Nangal Dam is around 20 km.
- Pin code: 174301, postal head office Santokhgarh.
Administration
District and regulatory contacts
The unit falls under District Una administration and the Himachal Pradesh state drugs control administration, which posts drugs inspectors at Una. Buyers should confirm licence status, endorsed product list and inspection history directly with the licensing authority before signing.
- District portal: hpuna.nic.in
- Assembly constituency: Haroli · Lok Sabha: Hamirpur
Compliance
Certification and regulatory status
The facility is a cGMP-approved unit licensed to manufacture tablets, capsules and syrups. Premises, plant and equipment are stated to be designed around Schedule M of the Drugs and Cosmetics Rules, 1945,1 following the core principles of WHO good manufacturing practice for pharmaceutical products.2
What the two licences mean
Form 25 and Form 28 read together
Form 25 is the licence to manufacture drugs other than those specified in Schedules C, C(1) and X — this covers ordinary tablets, capsules and syrups. Form 28 is the licence to manufacture drugs specified in Schedules C and C(1), excluding Schedule X, which is the category that covers biological and special products such as vitamin and hormone preparations.
Holding both is normal for a plant with a multivitamin and antioxidant range, but the two licence copies carry different endorsed product lists. Ask for the full, unredacted Form 25 and Form 28, both product schedules, and the current renewal status before you value the business.
Quality systems
What to inspect on site
- Approved SOP set and its revision history, including change control and deviation records.
- Purified water system qualification, sanitisation records and trend data — see FDA guidance on high-purity water systems for the expectations an auditor will apply.
- Equipment and area qualification files (DQ/IQ/OQ/PQ), plus HVAC validation for the antibiotic and general areas.
- Batch manufacturing records and stability data for the fastest-moving products.
- If regulated-market export is a goal later, compare current systems against WHO-GMP and USFDA expectations.
Honest correction: a state cGMP approval is not a WHO-GMP certificate and does not carry a WHO-GMP Certificate of Pharmaceutical Product. No WHO-GMP, ISO or export-market certification has been disclosed for this unit. Treat it as a domestic-market plant unless the seller produces documents that say otherwise.
Decision support
Due diligence score
A conservative reading of the disclosed information only. Categories with thin disclosure are scored low on purpose — a low score here means missing evidence, not a proven weakness.
Overall, disclosed information only
15 of 25 points. Expect this to move once financials and licence copies are shared.
Before you sign
Buyer checklist
Tick items as you clear them. Nothing is stored or sent — the list resets when you reload the page.
Checklist progress
0 of 11 items cleared
Numbers
Investment snapshot
Only the purchase price and the EBITDA margin band have been disclosed. Everything else is marked as such, rather than filled in with an estimate.
Indicative payback model
Test the deal against your own numbers
Enter the turnover and extra investment you expect. The figures below are produced from your inputs, not from seller data.
Read this before using the numbers: the 15–25% EBITDA band, the 250+ formulation count and the 30-client figure are seller-provided and unaudited. The calculator above works on figures you type in. It ignores interest, depreciation, tax, stamp duty and transfer costs, and is not a valuation, forecast or financial advice. Have a chartered accountant and a lawyer run the actual numbers.
Data quality
Three points that need clarification
- Manpower: 16 or 30? The listing information gives a 16-member team across Production, QC, QA and Engineering in one place and a 30-employee workforce in another. Both may be true if 16 is the technical headcount and 30 is total headcount including operators and packing staff, but that has not been confirmed. Ask for the payroll register.
- Plot versus built-up area. 800 square yards is about 7,200 sq. ft. of land against 12,000 sq. ft. constructed, which means the building is multi-level or close to full ground coverage. Any claim of open space for lateral expansion should be checked against the approved building plan and the permitted floor area ratio.
- Product range is not capacity. “250+ formulations” describes approved products, not output. Ask for tablets, capsules and bottles per shift, machine-wise, and reconcile it with electricity consumption.
If you are comparing this against building new, run the numbers through the pharma plant setup cost calculator. If the plan is to load the plant with your own brands, see how PCD and propaganda-cum-distribution models work. Buyers who need sterile capacity instead should look at injectable manufacturing, which this unit is not licensed for.
FAQs
Questions buyers ask about this unit
Request licences, machinery list and financials
Send an enquiry and we will share the available documents and arrange a site visit at Tahliwal. Independent verification and professional due diligence are recommended before any commitment.
More listings and advisory: contact Laafon Galaxy Pharmaceuticals.
References
- Central Drugs Standard Control Organisation. Schedule M — Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products. Ministry of Health and Family Welfare, Government of India.
- World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series.
Listing details, capacities, certifications, licence numbers, workforce figures, availability and commercial figures are supplied by the seller for enquiry purposes and should be independently verified. Licence numbers are shown partially redacted; full numbers are provided to serious buyers on request. This content is not legal, regulatory, investment or financial advice.
